<DOC>
	<DOCNO>NCT00004831</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine efficacy cysteine hydrochloride prevent decrease photosensitivity patient erythropoietic protoporphyria .</brief_summary>
	<brief_title>Study Cysteine Hydrochloride Erythropoietic Protoporphyria</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control , crossover study . Patients randomly assign 1 2 group receive cysteine hydrochloride orally twice daily , 2 capsule breakfast 2 lunch . Group 1 receives cysteine hydrochloride drug ingestion period 1 follow placebo period 2 . Group 2 receive placebo period 1 follow cysteine hydrochloride period 2 . Both group ingest placebo 1 week period . Each drug ingestion period last 8 week . Follow phone call make end month 1 3 . All patient schedule follow visit end drug ingestion period .</detailed_description>
	<mesh_term>Protoporphyria , Erythropoietic</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Documented erythropoietic protoporphyria Determination elevate protoporphyrin within past year Experiencing photosensitivity Prior/Concurrent Therapy No concurrent use betacarotene Patient Characteristics Other : Not pregnant nursing Fertile female patient must use effective contraception study 3 week thereafter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 1998</verification_date>
	<keyword>erythropoietic protoporphyria</keyword>
	<keyword>inborn error metabolism</keyword>
	<keyword>porphyria</keyword>
	<keyword>rare disease</keyword>
</DOC>